Platelet Disorders are conditions in which platelet number, production, function, survival or distribution is abnormal, resulting in impaired or excessive primary haemostasis. Platelets are small anucleate cellular fragments derived from megakaryocytes in the bone marrow and circulate in the blood where they rapidly respond to vascular injury. They adhere to exposed subendothelial structures, become activated, release signalling molecules and aggregate to form an initial platelet plug.
Disorders can therefore produce bleeding when platelet quantity or function is insufficient, or thrombosis when platelet activity is excessive or when the broader haemostatic environment promotes inappropriate platelet activation. Thrombocytopenia refers to an abnormally low platelet count, whereas thrombocytosis refers to an elevated count. Qualitative platelet disorders involve abnormal function despite a normal or near-normal platelet number and may be inherited or acquired.
Important mechanisms include reduced bone-marrow production, increased peripheral destruction, abnormal consumption, sequestration in an enlarged spleen, inherited receptor defects, medication effects, systemic illness and clonal disorders of blood-forming cells. Because platelets are central to primary haemostasis, many platelet disorders produce petechiae, purpura, epistaxis, gum bleeding, heavy menstrual bleeding and prolonged bleeding from superficial injuries.
Platelet production begins with haematopoietic stem cells in the bone marrow and proceeds through megakaryocyte development. Mature megakaryocytes extend cytoplasmic processes into marrow sinusoids, releasing platelets into circulation. Platelet formation is regulated principally by thrombopoietin, produced largely by the liver and interacting with the thrombopoietin receptor on megakaryocytic progenitors and platelets. Circulating platelets normally survive for approximately seven to ten days, although the precise lifespan varies with physiological and pathological conditions.
The spleen participates in platelet sequestration, so splenomegaly can lower the number of platelets circulating in peripheral blood without necessarily reducing total platelet mass to the same degree. Low platelet counts can therefore arise through decreased production, increased destruction, increased consumption or abnormal distribution. Bone-marrow failure, infiltration, nutritional deficiency, chemotherapy and certain infections can suppress production. Immune mechanisms can accelerate destruction, while disseminated coagulation, severe inflammation and other systemic conditions can consume platelets. Accurate diagnosis consequently requires understanding platelet physiology rather than treating the numerical count as a complete description of haemostatic function.
Thrombocytopenia encompasses a wide spectrum of disorders. Immune thrombocytopenia is characterised by immune-mediated platelet destruction and impaired platelet production, often resulting in isolated thrombocytopenia after other causes have been excluded. Drug-induced thrombocytopenia can result from immune destruction or marrow suppression and may occur with a variety of medicines. Heparin-induced thrombocytopenia is a particularly important immune-mediated condition because antibodies against complexes involving platelet factor 4 can cause marked platelet activation and paradoxically increase thrombosis risk despite the reduced platelet count.
Thrombotic thrombocytopenic purpura involves severe deficiency of ADAMTS13 activity, allowing unusually large von Willebrand factor multimers to promote platelet-rich microvascular thrombosis and organ injury. Haemolytic uraemic syndrome similarly combines thrombocytopenia with microangiopathic haemolytic anaemia and organ dysfunction. Disseminated intravascular coagulation causes widespread coagulation activation and consumption of platelets and coagulation factors. These examples demonstrate why the phrase Platelet Disorders covers mechanisms with very different treatments and risks.
Thrombocytosis can be reactive or clonal. Reactive thrombocytosis occurs when another process stimulates increased platelet production, including infection, inflammation, tissue injury, blood loss or iron deficiency. The platelet increase generally reflects an appropriate marrow response to an external stimulus rather than an intrinsic malignant platelet-producing disorder. Clonal thrombocytosis can occur in myeloproliferative neoplasms such as essential thrombocythaemia, in which a genetically abnormal haematopoietic clone produces excessive megakaryocytes and platelets.
Mutations involving genes such as JAK2, CALR and MPL can contribute to these disorders. Very high platelet counts do not automatically mean that thrombosis will occur, because platelet function and other haemostatic variables matter. Some patients with clonal disease can paradoxically develop bleeding because extremely high platelet counts may be associated with acquired von Willebrand factor abnormalities. Assessment therefore considers the magnitude and persistence of thrombocytosis, associated blood-count abnormalities, inflammatory conditions, iron status, clinical history and molecular findings.
Qualitative platelet disorders may be inherited or acquired. Glanzmann thrombasthenia results from severe dysfunction of the platelet integrin alpha IIb beta 3, impairing fibrinogen-mediated platelet aggregation. Bernard-Soulier syndrome involves abnormalities of the platelet glycoprotein Ib-IX-V complex, impairing adhesion to von Willebrand factor and often producing large platelets as well as thrombocytopenia. Storage-pool disorders impair platelet granule contents or release, reducing the amplification of platelet activation.
Acquired platelet dysfunction is considerably more common and can occur with medicines such as aspirin and other antiplatelet agents, which interfere with pathways required for platelet activation. Uraemia can also impair platelet function, producing bleeding despite a platelet count that may be normal. Liver disease can affect platelet number and function through splenic sequestration, altered thrombopoietin production and broader haemostatic disturbances. These disorders demonstrate that platelet quantity alone cannot fully predict bleeding tendency.
Evaluation of Platelet Disorders normally begins with a complete blood count, blood film and careful history. The blood film can identify platelet size abnormalities, clumping that produces a falsely low automated count, abnormal blood-cell morphology and evidence of microangiopathic haemolysis. Repeating the platelet count in a different anticoagulant can sometimes resolve laboratory artefacts caused by platelet aggregation in the test tube. Medication history is particularly important because antiplatelet and anticoagulant drugs can significantly alter haemostasis.
Coagulation studies, liver and renal tests, inflammatory markers, haemolysis investigations and specialist platelet-function testing may be appropriate depending on the clinical picture. Bone-marrow examination is not required for every low or high platelet count but can be important when marrow disease, dysplasia or a clonal disorder is suspected. Interpretation must integrate laboratory findings with bleeding or thrombotic symptoms because an abnormal platelet count does not necessarily establish the mechanism or clinical severity.
Treatment depends entirely on the underlying disorder. Severe thrombocytopenic bleeding may require platelet transfusion, but transfusion is not automatically appropriate for every low count and can be ineffective or inappropriate in immune-mediated conditions unless clinically indicated. Immune thrombocytopenia may be treated with corticosteroids, intravenous immunoglobulin and other immune-directed therapies depending on severity and duration, while thrombopoietin-receptor agonists can stimulate platelet production in selected patients.
Thrombotic thrombocytopenic purpura requires urgent plasma exchange and targeted therapy because untreated disease can be rapidly fatal. Heparin-induced thrombocytopenia requires immediate discontinuation of heparin and use of an alternative anticoagulant rather than platelet transfusion as routine treatment. Essential thrombocythaemia may require risk-adapted reduction of thrombosis risk and treatment of the underlying clonal disorder. The central principle is that the platelet count must be interpreted within its biological and clinical context rather than treated as an isolated target.
Platelet Disorders are important because primary haemostasis intersects with nearly every major component of medicine. Before surgery, clinicians need to know whether a low platelet count represents an immediate bleeding risk, a stable chronic condition or a laboratory artefact. During pregnancy, thrombocytopenia has multiple possible causes ranging from benign gestational thrombocytopenia to hypertensive disorders and immune disease. In cancer care, chemotherapy, marrow infiltration and immune therapies can alter platelet production or survival.
In critical illness, platelet consumption can accompany sepsis, disseminated coagulation and major tissue injury. Conversely, excessive platelet activation contributes to arterial thrombosis in conditions such as myocardial infarction and ischaemic stroke, explaining the widespread use of antiplatelet medicines. A common misconception is that every thrombocytopenic patient is equally likely to bleed; bleeding risk depends on platelet count, platelet function, the integrity of vascular tissues, concurrent coagulation abnormalities and the underlying cause. Platelet Disorders therefore represent a broad physiological and clinical category spanning benign laboratory abnormalities, inherited bleeding syndromes, immune conditions, emergency microvascular diseases and clonal haematological disorders.
